Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pegvaliase
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
BioMarin Reports Positive PALYNZIQ Data in Adolescents with PKU
Details : Palynziq (pegvaliase) is a PEG PAL enzyme that converts phenylalanine to ammonia and trans-cinnamic acid. It reduces blood phenylalanine concentrations in patients with PKU.
Product Name : Palynziq
Product Type : Enzyme
Upfront Cash : Inapplicable
April 02, 2025
Lead Product(s) : Pegvaliase
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegvaliase
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
January 17, 2025
Lead Product(s) : Pegvaliase
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegvaliase
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
March 08, 2022
Lead Product(s) : Pegvaliase
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegvaliase
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
October 03, 2018
Lead Product(s) : Pegvaliase
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegvaliase
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
March 28, 2013
Lead Product(s) : Pegvaliase
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegvaliase
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
March 22, 2012
Lead Product(s) : Pegvaliase
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegvaliase
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
October 01, 2010
Lead Product(s) : Pegvaliase
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable